Bruker Announces Closing of Chemspeed Technologies AG Acquisition
07 Marzo 2024 - 6:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) is pleased to announce the
successful closing of its acquisition of Chemspeed Technologies AG,
a leading Swiss provider of automated laboratory R&D and QC
workflow solutions. This acquisition, first announced in January
2024, marks another significant milestone in Bruker’s expansion in
vendor-agnostic scientific software, R&D and QC digitalization,
and laboratory automation – altogether an important initiative
within Bruker’s strategic Project Accelerate 2.0 portfolio
transformation.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240307671888/en/
Chemspeed’s modular, compact FLEX
automation workstations enhance chemical and materials science
R&D and lab productivity and quality, as well as improve return
on R&D investment (Photo: Business Wire)
Mr. Bernd Gleixner, President of the new Automation Division at
Bruker BioSpin, and now Managing Director of Chemspeed, commented:
“We are excited about the opportunities this acquisition brings,
and we warmly welcome the excellent Chemspeed team to Bruker. Going
forward, Chemspeed will continue to operate as a vendor-agnostic,
standalone business within Bruker, maintaining its commitment to
industry-leading automated laboratory solutions and customer
service.”
As part of Bruker, Chemspeed is expected to be near break-even
for the remaining three quarters of 2024, with approximately $10
million of revenue per quarter, as it transitions to US GAAP
reporting and aligns with Bruker’s revenue recognition policies. By
2025, we anticipate Chemspeed to be 2-3 cents accretive to Bruker’s
non-GAAP EPS. Going forward, we expect high-single digit to low
double-digit organic revenue growth and steady, significant margin
expansion. The Chemspeed acquisition is a testament to Bruker’s
commitment to strategic expansion and innovation in the fields of
automated R&D and QC laboratory solutions, lab digitalization
and scientific software.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307671888/en/
Investors: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media: Markus Ziegler Sr. Director and Head of Group
Marketing Bruker BioSpin T: +49 172 3733531 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024